- In triple-negative breast cancer (TNBC), patients aged >75 years have worse recurrence-free survival (RFS), distant disease-free survival (DDFS), and breast cancer-specific survival (BCSS) than their younger counterparts (aged
- The survival disadvantages disappeared in this Swedish registry study after the authors controlled for adjuvant/neoadjuvant chemotherapy.
Why this matters
- The findings suggest that new therapeutic options are needed for older patients because they are not electing chemotherapy.
- Analysis of a Swedish regional breast cancer registry data for patients with stage I-IV primary TNBC (2007-2015).
- Data for patients aged >75 years (n=96) were compared with data for patients aged
- Funding: King Gustaf V Jubilee Clinic Cancer Research Foundation; others.
- Median follow-up, 55 months.
- Younger vs older patients:
- Similar stage at diagnosis, lymphovascular invasion.
- Worse histopathologic grade (P=.006) and Ki67 index (median, 80% vs 70%; P=.002).
- More likely to receive adjuvant/neoadjuvant chemotherapy (96% vs 12%; P=.0005).
- More likely to have brain (P=.016) and liver (P=.047) metastases.
- Compared with younger patients, older patients had worse (HRs; 95% CIs):
- RFS: 2.22 (1.12-4.43).
- DDFS: 2.13 (1.07-4.27).
- BCSS: 2.78 (1.33-5.81).
- Differences disappeared after adjustment for receipt of chemotherapy.